Principali pubblicazioni e brevetti
- Ulivieri A, Morgante A, Magi F, Salehi LB, Lavra L. Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021. Epidemiol Prev. 2022 Sep-Dec;46(5-6):367-375. doi: 10.19191/EP22.5-6.A461.088.
- Ulivieri A, Lavra L, Magi F, Morgante A, Calò L, Polisca P, Salehi LB, Sciacchitano Thyroid hormones regulate cardiac repolarization and QT- interval related gene expression in hiPSC cardiomyocytes. Sci Rep. 2022 Jan 12;12(1):568. doi: 10.1038/s41598-021-04659-w.
- Sciacchitano S, Capalbo C, Napoli C, Negro A, De Biase L, Marcolongo A, Anibaldi P, Salvati V, Petrella L, Merlo L, Alampi D, Alessandri E, Loffredo C, Ulivieri A, Lavra L, Magi F, Morgante A, Salehi LB, De Vitis C, Mancini R, Coluzzi F, Rocco M. Nonthyroidal illness syndrome (NTIS) in severe COVID-19 patients: role of T3 on the Na/K pump gene expression and on hydroelectrolytic J Transl Med. 2021 Dec 3;19(1):491. doi: 10.1186/s12967-021-03163-z.
- Lavra L, Magi F, Ulivieri A, Morgante A, Paulis M, Sala L, Pedrazzini M, Polisca P, Rocchetti M, Calò L, Sciacchitano S, Salehi Generation and characterization of the human induced pluripotent stem cell (hiPSC) line NCUFi001-A from a patient carrying KCNQ1 G314S mutation. Stem Cell Res. 2021 Jul;54:102418. doi: 10.1016/j.scr.2021.102418.
- Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Ricci A. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Int J Mol Sci. 2018 Jan 26;19(2):379. doi: 10.3390/ijms19020379.
- Sciacchitano S, Lavra L, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Trovato M, Drago C, Bartolazzi Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology. Oncotarget. 2017 Jul 25;8(30):49421-49442. doi: 10.18632/oncotarget.17220.
- Spath L, Ulivieri A, Lavra L, Fidanza L, Carlesimo M, Giubettini M, Narcisi A, Luciani E, Bucci B, Pisani D, Sciacchitano S, Bartolazzi A. Antiproliferative Effects of 1α-OH-vitD3 in Malignant Melanoma: Potential Therapeutic Sci Rep. 2017 Jan 11;7:40370. doi: 10.1038/srep40370.
- Prodosmo A, Buffone A, Mattioni M, Barnabei A, Persichetti A, De Leo A, Appetecchia M, Nicolussi A, Coppa A, Sciacchitano S, Giordano C, Pinnarò P, Sanguineti G, Strigari L, Alessandrini G, Facciolo F, Cosimelli M, Grazi GL, Corrado G, Vizza E, Giannini G, Soddu S. Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. J Exp Clin Cancer Res. 2016 Sep 6;35(1):135. doi: 1186/s13046-016-0410-3. Erratum in: J Exp Clin Cancer Res. 2016 Nov 28;35(1):185.
- Festuccia F, Jafari MT, Moioli A, Fofi C, Barberi S, Amendola S, Sciacchitano S, Punzo G, Menè Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol. 2017 Apr;30(2):271-279. doi: 10.1007/s40620- 016-0334-1.
- Sciacchitano S, Lavra L, Ulivieri A, Magi F, Porcelli T, Amendola S, De Francesco GP, Bellotti C, Trovato MC, Salehi LB, Bartolazzi Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules. Endocrine. 2016 Oct;54(1):139-147. doi: 10.1007/s12020-015-0774-8.
- Lavra L, Catini A, Ulivieri A, Capuano R, Baghernajad Salehi L, Sciacchitano S, Bartolazzi A, Nardis S, Paolesse R, Martinelli E, Di Natale C. Investigation of VOCs associated with different characteristics of breast cancer cells. Sci Rep. 2015 Aug 25;5:13246. doi: 10.1038/srep13246.
- Ulivieri A, Cardillo G, Manente L, Paone G, Mancuso AP, Vigna L, Di Stasio E, Gasbarra R, Girlando S, Leone Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. Oncotarget. 2015 Aug 14;6(23):19868-79. doi: 10.18632/oncotarget.4503.
Il laboratorio di Ricerca Biomedica ha inoltre pubblicato un brevetto nell’ambito del progetto di ricerca oncologico: brevetto N° PCT/IT2017000137 – Metodo per la diagnosi in vitro del carcinoma tiroideo.